Cover Image
市場調查報告書

全球血中循環核酸(CNA)的非侵入性癌症診斷的市場

Circulating Nucleic Acids (CNAs) Based Non-Invasive Cancer Diagnostics: Global Market Report

出版商 Veracity Health 商品編碼 309759
出版日期 內容資訊 英文 219 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球血中循環核酸(CNA)的非侵入性癌症診斷的市場 Circulating Nucleic Acids (CNAs) Based Non-Invasive Cancer Diagnostics: Global Market Report
出版日期: 2014年07月28日 內容資訊: 英文 219 Pages
簡介

本報告提供全球血中循環核酸(CNA:Circulating Nucleic Acids)的非侵入性癌症診斷的市場相關調查、CNA種類與概要、利用CNA的各種診斷手法、癌症的發病相關統計、使用CNA的癌症診斷主要產品、CNA的癌症診斷收益分析及預測、地區與主要國家的明細、影響市場成長因素分析、競爭環境與市場佔有率、主要經營者簡介等彙整資料。

摘要整理

第1章 關於本報告

  • 本報告書的背景
  • 本報告書的目的、提供內容
  • 調查手法

第2章 血中循環核酸(CNA:Circulating Nucleic Acids)的背景

  • 關於血中循環核酸
  • 血中循環核酸的類別
    • 血中循環無細胞DNA
    • 血中循環細胞外DNA
    • RNA
      • microRNA(miRNA)
      • miRNA模仿體、抑制劑
      • siRNA(Small Interfering RNA)
      • RNAi(RNA Interference)
  • 診斷工具的血中循環核酸
    • 癌症生物標記的血中循環DNA
    • 在產前診斷的血中循環DNA的利用
    • 癌症生物標記的血中循環RNA
    • 妊娠中的血中循環RNA
  • 血中循環核酸的檢測所採用的手法

第3章 癌症:疾病的發病率、得病率的統計分析

  • 簡介
  • 全球統計摘要:發病率估計、死亡率、5年得病率
    • 癌症的各類型
    • 男性、癌症的各類型
    • 女性、癌症的各類型
  • WHO的南北美洲的統計摘要:發病率估計、死亡率、5年得病率:癌症的各類型
  • WHO的歐洲地區的統計摘要:發病率估計、死亡率、5年得病率:癌症的各類型
  • WHO的非洲的統計摘要:發病率估計、死亡率、5年得病率:癌症的各類型
  • WHO的地中海東部的統計摘要:發病率估計、死亡率、5年得病率:癌症的各類型
  • WHO的東南亞的統計摘要:發病率估計、死亡率、5年得病率:癌症的各類型
  • WHO的太平洋西部的統計摘要:發病率估計、死亡率、5年得病率:癌症的各類型

第4章 CNA的癌症診斷市場:收益分析

  • 簡介
  • 市場動態
    • 市場促進因素
    • 市場成長的阻礙要素
  • 主要的CNA癌症診斷產品
  • 市場收益分析
    • 全球市場收益分析
    • 全球市場收益分析:各地區
    • 市場收益分析:各主要國家

第5章 CNA的癌症診斷市場:市場佔有率分析

  • 市場佔有率分析
    • 全球市場佔有率分析
    • 市場佔有率分析:各地區
    • 市場佔有率分析:各主要國家

第6章 企業簡介

  • Abbott Laboratories (Abbott Molecular)
  • Affymetrix Inc
  • Autogenomics
  • Becton Dickinson and Company (BD)
  • Beckmann Coulter, Inc (Danaher Corporation)
  • bioMerieux
  • Cancer Genetics, Inc
  • Cepheid
  • Dako (Agilent)
  • Epigenomics
  • Hologic Gen-Probe
  • Illumina
  • Ipsogen (Qiagen)
  • Luminex
  • MolecularMD
  • Myriad Genetics Laboratories
  • Novartis Diagnostics
  • Ortho-Clinical Diagnostics (The Carlyle Group)
  • Oxford Gene Technology (OGT)
  • Qiagen N.V
  • Roche
  • Siemens
  • Sysmex Corporation
  • Thermo Fisher Scientific
  • Ventana (Roche)

用語

目錄

The aim of this report was to review recent advances in use of circulating cell-free miRNA, DNA and mRNA as novel biomarkers which can be used for the detection and diagnosis of cancer, and the impact on making the ongoing research closer to clinical application. The report will also provide a market analysis of the market value, growth rates, market development as well as examining the dynamics and factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry players, and the factors influencing the market shares of both the major market suppliers and smaller indigenous manufacturers in local markets.

The data collection and forecasting methods used in the preparation of this report are broadly divided into three methods. These are primary data and information gathering, secondary data and information gathering and market share analysis and market forecast prediction. Information and data including estimates on market values, growth rates and market share data were gathered from the methods described and were incorporated into proprietary computer forecasting and market share analysis models. The forecast model was used to derive market estimates for future years. It incorporates a rate factor, which helps determine the speed with which the market develops, which is similar to that observed for markets for other medical products and is adjusted to match historic data for the market under analysis.

Table of Contents

ES.1. Introduction to the Circulating Nucleic Acid Market Report

ES.2. Background to Circulating Nucleic Acids

ES.3. Cancer: A Statistical Analysis of the Disease Incidence and Prevalence

ES.4. CNA Based Cancer Diagnostics Market: Revenue Analysis

  • Exhibit E.S. 1: Global Market Revenue Forecast - CNA Based Non-invasive Cancer Diagnostic Products (2010 - 2020)

ES.5. CNA Based Cancer Diagnostics Market: Market Share Analysis

  • Exhibit E.S. 2: Global Market Share Analysis - CNA Based Non-invasive Cancer Diagnostic Products (2013)
  • Exhibit E.S. 3: Global Market Share Analysis - CNA Based Non-invasive Cancer Diagnostic Products (2013)

ES.6. Company Profiles

  • 1.1. Report Background
  • 1.2. Report Objectives and Deliverables
  • 1.3. Methodology
  • 2.1. Introduction to Circulating Nucleic Acids (CNAs)
  • Exhibit 2.1: Major Developments in Understanding Nucleic Acids and their Cellular Roles
  • Exhibit 2.2: Circulating DNA Concentrations in Blood of Healthy Donors and Selected Cancer Patients
  • 2.2. Categories of Circulating Nucleic Acids
    • 2.2.1. Circulating Cell-Free DNA
    • 2.2.2. Circulating Extracellular DNA
    • 2.2.3. RNA
      • 2.2.3.1. microRNAs (miRNAs)
      • 2.2.3.2. miRNA Mimics and Inhibitors
      • 2.2.3.3. Small Interfering RNA (siRNA)
      • 2.2.3.4. RNA Interference (RNAi)
  • 2.3. Circulating Nucleic Acids as a Diagnostic Tool
    • 2.3.1. Circulating DNA as a Biomarker of Cancer
    • 2.3.2. Use of Circulating DNA for Prenatal Diagnosis
    • 2.3.3. Circulating RNA as a Biomarker of Cancer
  • Exhibit 2.3: Circulating Tumour-Associated miRNAs as potential biomarkers in Lung Cancer
  • Exhibit 2.4: Circulating Tumour-Associated miRNAs as potential biomarkers in Breast Cancer
  • Exhibit 2.5: Circulating Tumour-Associated miRNAs as potential biomarkers in Prostate Cancer
  • Exhibit 2.6: Circulating Tumour-Associated miRNAs as potential biomarkers in Ovarian Cancer
  • Exhibit 2.7: Circulating Tumour-Associated miRNAs as potential biomarkers in Bladder Cancer
  • Exhibit 2.8: Circulating Tumour-Associated miRNAs as potential biomarkers in Pancreatic Cancer
  • Exhibit 2.9: Circulating Tumour-Associated miRNAs as potential biomarkers in Gastric Cancer
  • Exhibit 2.10: Circulating Tumour-Associated miRNAs as potential biomarkers in Liver Cancer
  • Exhibit 2.11: Circulating Tumour-Associated miRNAs as potential biomarkers in Colo-Rectal Cancer
  • Exhibit 2.12: Circulating Tumour-Associated miRNAs as potential biomarkers in Oral Cancer
  • Exhibit 2.13: Circulating Tumour-Associated miRNAs as potential biomarkers in Esophageal Cancer
  • 2.3.4. Circulating RNA in Pregnancy
  • 2.4. Methods Used for the Detection of Circulating Nucleic Acids
    • Exhibit 2.4: Top molecular CNA Characterisation Techniques
    • Exhibit 2.5: Top molecular CNA Characterisation Techniques
  • 3.1. Introduction
  • 3.2. Global Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence
    • Exhibit 3.1: Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (2012)
    • 3.2.1. Global Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence (Both Sexes) by Cancer Type
      • Exhibit 3.2: Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
    • 3.2.2. Global Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence (Male) by Cancer
      • Exhibit 3.3: Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (By Male) by Cancer Type (2012)
    • 3.2.3. Global Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.4: Summary Statistics: Estimated Incidence, Mortality and 5-year Prevalence (By Female) by Cancer Type (2012)
  • 3.3. WHO Americas Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.5: WHO Americas Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
  • 3.4. WHO European Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.6: WHO European Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
  • 3.5. WHO African Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.7: WHO African Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
  • 3.6. WHO Eastern Mediterranean Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.8: WHO Eastern Mediterranean Eastern Mediterranean Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
  • 3.7. WHO South East Asia Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.9: WHO South East Asia Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
  • 3.8. WHO Western Pacific Region Summary Statistics: Estimated Incidence, Mortality and 5-Year Prevalence by Cancer Type
    • Exhibit 3.10: WHO Western Pacific Region Summary Statistics (Global): Estimated Incidence, Mortality and 5-year Prevalence (Both Sexes) by Cancer Type (2012)
  • 4.1. Introduction
  • 4.2. Market Dynamics
    • 4.2.1. Market Drivers
      • 4.2.1.1. Evolving Paradigm Shift in Disease Diagnostics
      • 4.2.1.2. Significant Advantages over Conventional Screening and Diagnostic Methods
      • 4.2.1.3. Research and Development of New and Innovative Enabling Technologies
    • 4.2.2. Market Restraints
      • 4.2.2.1. Securing Appropriate Reimbursement Schedules
      • 4.2.2.2. Social, Ethical and Regulatory Issue for Implementation of Circulating Nucleic Acid Diagnostic Technologies
      • 4.2.2.3. Technical Issues: Sample Collection, Handling, Extraction, Transportation and Storage etc Cause Concerns over Practical Use of Circulating Nucleic Acids
  • 4.3. Selected CNA Cancer Diagnostic Products
    • Exhibit 4.1: Featured CNA Cancer Diagnostic Products
  • 4.4. Market Revenue Analysis
    • 4.4.1. Global Market Revenue Analysis
      • 4.4.1.1. Total Market Revenue Analysis
        • Exhibit 4.2: Global Market Revenue Forecast (2010 - 2020)
    • 4.1.1. Market Revenue Analysis by Geographic Region
      • Exhibit 4.3: Global Market Revenue Forecast (2009 - 2019)
      • Exhibit 4.4: Market Revenue Forecast by Geographic Countries - (2010 - 2020)
      • Exhibit 4.5: Percentage Share of Global Market Revenue Forecast by Geographic Region - CNA Based Cancer Diagnostics (2010 - 2020)
      • Exhibit 4.6: Percentage Share of Global Market Revenue Forecast by Geographic Region - CNA Based Cancer Diagnostics (2010 - 2020)
    • 4.1.2. Market Revenue Analysis by Selected Country
      • Exhibit 4.6: Market Revenue Forecast by Selected Countries - (2010 - 2020)
      • Exhibit 4.7: Market Revenue Forecast by Selected Countries - (2010 - 2020)
  • 5.1. Market Share Analysis
    • 5.1.1. Global Market Share Analysis
      • Exhibit 5.1: Global Market Share Analysis - CNA Based Non-invasive Cancer Diagnostic Products (2013)
      • Exhibit 5.2: Global Market Share Analysis - CNA Based Non-invasive Cancer Diagnostic Products (2013)
    • 5.5.2. Market Share Analysis by Geographic Region
      • Exhibit 5.3: Market Share Analysis by Geographic Region - Non-invasive Cancer Diagnostic (2013)
    • 5.5.3. Market Share Analysis by Selected Country
      • Exhibit 5.4: Market Share Analysis by Selected Country - Non-invasive Prenatal Diagnostics (2013)
  • 6.1. Abbott Laboratories (Abbott Molecular)
  • 6.2. Affymetrix Inc
  • 6.3. Autogenomics
  • 6.4. Becton Dickinson and Company (BD)
  • 6.5. Beckmann Coulter, Inc (Danaher Corporation)
  • 6.6. bioMérieux
  • 6.7. Cancer Genetics, Inc
  • 6.8. Cepheid
  • 6.9. Dako (Agilent)
  • 6.10. Epigenomics
  • 6.11. Hologic Gen-Probe
  • 6.12. Illumina
  • 6.13. Ipsogen (Qiagen)
  • 6.14. Luminex
  • 6.15. MolecularMD
  • 6.16. Myriad Genetics Laboratories
  • 6.17. Novartis Diagnostics
  • 6.18. Ortho-Clinical Diagnostics (The Carlyle Group)
  • 6.19. Oxford Gene Technology (OGT)
  • 6.20. Qiagen N.V
  • 6.21. Roche
  • 6.22. Siemens
  • 6.23. Sysmex Corporation
  • 6.24. Thermo Fisher Scientific
  • 6.25. Ventana (Roche)
  • Glossary of Acronyms
Back to Top